We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals
ALNY

496 hedge funds and large institutions have $26.7B invested in Alnylam Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 118 funds opening new positions, 170 increasing their positions, 151 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

203% more first-time investments, than exits

New positions opened: 118 | Existing positions closed: 39

83% more funds holding in top 10

Funds holding in top 10: 6 → 11 (+5)

62% more capital invested

Capital invested by funds: $16.5B → $26.7B (+$10.2B)

18% more funds holding

Funds holding: 421 → 496 (+75)

17.7% more ownership

Funds ownership: 93.9% → 111.6% (+18%)

13% more repeat investments, than reductions

Existing positions increased: 170 | Existing positions reduced: 151

11% more call options, than puts

Call options by funds: $298M | Put options by funds: $270M

Holders
496
Holders Change
+75
Holders Change %
+17.81%
% of All Funds
8.54%
Holding in Top 10
11
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+83.33%
% of All Funds
0.19%
New
118
Increased
170
Reduced
151
Closed
39
Calls
$298M
Puts
$270M
Net Calls
+$28.8M
Net Calls Change
-$110M

Top Buyers

1
N
Nuveen
North Carolina
+$3.11B
2
Capital World Investors
Capital World Investors
California
+$698M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$133M
4
Holocene Advisors
Holocene Advisors
New York
+$123M
5
Invesco
Invesco
Georgia
+$109M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$625M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$262M
3
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$142M
4
AllianceBernstein
AllianceBernstein
Tennessee
-$114M
5
AG
Artal Group
Luxembourg
-$87.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
EAM
151
Erste Asset Management
Austria
$6.48M -$954K -5,000 -14%
Tudor Investment Corp
152
Tudor Investment Corp
Connecticut
$5.98M +$5.34M +28,014 +1,518%
EAM
153
EFG Asset Management
Oregon
$5.75M +$359K +1,880 +7%
LIP
154
Liontrust Investment Partners
United Kingdom
$5.71M -$973K -5,100 -15%
SEI Investments
155
SEI Investments
Pennsylvania
$5.68M +$399K +2,094 +8%
Walleye Trading
156
Walleye Trading
New York
$5.65M +$3.08M +16,154 +134%
SCM
157
Soleus Capital Management
Connecticut
$5.4M +$1.32M +6,900 +34%
Toronto Dominion Bank
158
Toronto Dominion Bank
Ontario, Canada
$5.35M -$11.6K -61 -0.2%
Mariner
159
Mariner
Kansas
$5.29M +$5.04M +26,444 New
Principal Financial Group
160
Principal Financial Group
Iowa
$5.29M -$970K -5,083 -16%
SCM
161
Shaolin Capital Management
Florida
$5.26M +$5.02M +26,300 New
Parnassus Investments
162
Parnassus Investments
California
$5.2M -$6.12M -32,068 -55%
WAM
163
Weiss Asset Management
Massachusetts
$4.89M +$4.66M +24,450 New
TAF
164
Tredje AP-fonden
Sweden
$4.77M +$4.55M +23,842 New
APG Asset Management
165
APG Asset Management
Netherlands
$4.74M +$1.41M +7,374 +47%
Mackenzie Financial
166
Mackenzie Financial
Ontario, Canada
$4.71M +$478K +2,508 +12%
FAF
167
Första AP-fonden
Sweden
$4.62M -$1.13M -5,900 -20%
SAM
168
Sectoral Asset Management
Quebec, Canada
$4.54M +$2.03M +10,650 +89%
FAF
169
Fjarde Ap-fonden
Sweden
$4.48M – – –
LAM
170
LifePro Asset Management
California
$4.38M +$4.18M +21,898 New
Allianz Asset Management
171
Allianz Asset Management
Germany
$4.35M -$5.33M -27,968 -56%
URS
172
Utah Retirement Systems
Utah
$4.32M +$38.1K +200 +0.9%
MCM
173
Moore Capital Management
New York
$4.25M +$4.05M +21,247 New
DnB Asset Management
174
DnB Asset Management
Norway
$4.2M -$46.5K -244 -1%
WorldQuant Millennium Advisors
175
WorldQuant Millennium Advisors
New York
$4.09M +$3.9M +20,426 New
5 6
7
8 9

ALNY Hedge Fund Activity: Q3 2022 in Review

496 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2022, worth a combined $26.7B — up 62% from $16.5B a quarter earlier.

Buyers outnumbered sellers: 118 funds opened new ALNY positions and 39 closed out — a net gain of 79 holders — while 170 added to existing stakes and 151 trimmed.

The largest buyer was Nuveen, adding an estimated $3.11B. The largest seller was T. Rowe Price Associates, cutting an estimated $625M.

  • 496 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2022, up from 421 in Q2 2022.
  • Funds reported $26.7B of Alnylam Pharmaceuticals stock for Q3 2022, up 62% quarter-over-quarter.
  • 118 funds opened new Alnylam Pharmaceuticals positions in Q3 2022 and 39 closed out, a net change of +79 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q3 2022 was Nuveen, an estimated $3.11B added.
  • The largest Alnylam Pharmaceuticals seller in Q3 2022 was T. Rowe Price Associates, an estimated $625M sold.

Based on aggregated 13F filings for Q3 2022.